These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 30002096)
1. Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. Li X; Jusko WJ; Cao Y J Pharmacol Exp Ther; 2018 Oct; 367(1):1-8. PubMed ID: 30002096 [TBL] [Abstract][Full Text] [Related]
2. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093 [TBL] [Abstract][Full Text] [Related]
3. Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor- Chen X; DuBois DC; Almon RR; Jusko WJ Drug Metab Dispos; 2017 Jul; 45(7):790-797. PubMed ID: 28411280 [TBL] [Abstract][Full Text] [Related]
4. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Li N; Betts KA; Messali AJ; Skup M; Garg V Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087 [TBL] [Abstract][Full Text] [Related]
6. Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. Chen X; Jiang X; Jusko WJ; Zhou H; Wang W J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):291-304. PubMed ID: 27119518 [TBL] [Abstract][Full Text] [Related]
7. Transcending conventional therapies: the role of biologic and other novel therapies. Sandborn WJ Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043 [TBL] [Abstract][Full Text] [Related]
9. Binding and functional comparisons of two types of tumor necrosis factor antagonists. Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039 [TBL] [Abstract][Full Text] [Related]
10. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. Doan QV; Chiou CF; Dubois RW J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801 [TBL] [Abstract][Full Text] [Related]
12. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611 [TBL] [Abstract][Full Text] [Related]
13. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
14. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges. Zheng S; McIntosh T; Wang W J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966 [TBL] [Abstract][Full Text] [Related]
15. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. Lim H; Lee SH; Lee HT; Lee JU; Son JY; Shin W; Heo YS Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518978 [TBL] [Abstract][Full Text] [Related]
16. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462 [TBL] [Abstract][Full Text] [Related]
17. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center. Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976 [TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Hamilton K; Clair EW Expert Opin Pharmacother; 2000 Jul; 1(5):1041-52. PubMed ID: 11249494 [TBL] [Abstract][Full Text] [Related]
19. Structure-activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction. Benveniste M; Mayer ML Br J Pharmacol; 1991 Sep; 104(1):207-21. PubMed ID: 1686203 [TBL] [Abstract][Full Text] [Related]
20. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. Bourne T; Fossati G; Nesbitt A BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]